Laquinimod in the treatment of relapsing remitting multiple sclerosis

References

• Bjartmar C, Kidd G, Mork S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000;48:893–901.
   PubMed Web of Science ®Google Scholar
• Ganter P, Prince C, Esiri C, et al. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol. 1999;25:459–467.
   PubMed Web of Science ®Google Scholar
• Brück W, Gold R, Lund BT, et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013;70(10):1315–1324.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Derfuss T, Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol [Internet]. 2015 Dec 24. doi:10.1007/s00415-015-7986-y.
   Web of Science ®Google Scholar
• Haase R, Kullmann JS, Ziemssen T. Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey. TAND. 2016 Mar 15. DOI:10.1177/1756285616634247.
   Google Scholar
• Karussis DM, Lehmann D, Slavin S, et al. Inhibition of acute experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol. 1993;34:654–660.
   PubMed Web of Science ®Google Scholar
• Karussis DM, Lehmann D, Slavin S, et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A. 1993;90:6400–6404.
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS: Part I. Trial design and clinical results. Neurology. 2000;54:1726–1733.
   PubMed Web of Science ®Google Scholar
• Wolinsky J, Narayana P, Noseworthy J, et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology. 2000;54(9):1734–1741.
   PubMed Web of Science ®Google Scholar
• Andersen O, Lycke J, Tollesson PO, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology. 1996;47:895–900.
   PubMed Web of Science ®Google Scholar
• Tan IL, Lycklmaà Nijeholt GJ, Polman CH, et al. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase III trails. Mult Scler. 2000;6:99–104.
   PubMed Web of Science ®Google Scholar
• Jonsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. Lund (Sweden): Active Biotech Research AB. J Med Chem. 2004;47(8):2075–2088.
   Google Scholar
• Brunmark C, Runström A, Ohlsson L, et al. The new orally active immunregulator laqunimod (ABR – 215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;130:163–172.
   PubMed Web of Science ®Google Scholar
• Jeffery DR, Pharr E, Zeid NA. Laquinimod in relapsing remitting multiple sclerosis. US Neurol. 2010;6(2):70–75.
   Google Scholar
• Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs. 2009;18(7):985–989.
   PubMed Web of Science ®Google Scholar
• Brück W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306:173–179. doi:10.1016/j.jns.2011.02.019.
   PubMed Web of Science ®Google Scholar
• Nerventra. European medicines agency; [ cited 2014 May 22]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002546/WC500171788.pdf
   Google Scholar
• Aharoni R, Saada R, Eilam R, et al. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2012;251:14–24.
   PubMed Web of Science ®Google Scholar
• Zou L, Abbas N, Volkmann I, et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology. 2002;42:731–739.
   PubMed Web of Science ®Google Scholar
• Mishra M, Wang J, Silva C, et al. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am J Pathol. 2012;181:642–651.
   PubMed Web of Science ®Google Scholar
• Gurevich M, Gritmann T, Orbach R, et al. Laquinimod suppress antigen presentation in relapsing–remitting multiple sclerosis: in-vitro high-throughput gene expression study. J Neuroimmunol. 2010;221:87–94.
   PubMed Web of Science ®Google Scholar
• Schulze-Topphoff U, Shetty A, Varrin-Doyer M, et al. Laqunimod, a quinoline 3 carboxamie, induces typ II myeloid cells that modulate central nervosus system autoimmunity. PLoS One. 2012;7(3):e33797.
   PubMed Web of Science ®Google Scholar
• Brück W, Pförtner R, Pham T, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012;124:411–424.
   PubMed Web of Science ®Google Scholar
• Moore S, Khalaj A, Yoon J, et al. Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis. Brain Behav. 2013;3(6):664–682.
   PubMed Web of Science ®Google Scholar
• Thöne J, Ellrichmann G, Seubert S, et al. Modulation of autoimmune demyelination by laqunimod via induction of brain derived neurotrophic factor. Am J Pathol. 2012;180:267–274.
   PubMed Web of Science ®Google Scholar
• Wegner C, Stadelmann C, Pförtner R, et al. Laqunimod interferes with migratory capacity of T cells and reduces IL 17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;227:133–143.
   PubMed Web of Science ®Google Scholar
• Toubi E, Nussbaum S, Staun-Ram E, et al. Laqunimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J Neuroimmunol. 2012;251:45–54.
   PubMed Web of Science ®Google Scholar
• Jolivel V, Luessi F, Masri J, et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain J Neurol. 2013;136(4):1048–1066.
   Web of Science ®Google Scholar
• Lund B, Kelland E, Hayardeny L, et al. Assessment of changes in immune measures of multiple sclerosis patients treated with laqunimod. J Neuroimmunol. 2013;263:108–115.
   PubMed Web of Science ®Google Scholar
• Kelland E, Gilmore W, Hayardeny L, et al. In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells. J Neurol Sci. 2014;346:66–74.
   PubMed Web of Science ®Google Scholar
• Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005;64(6):987–991.
   PubMed Web of Science ®Google Scholar
• Comi G, Rovaris M, Abramsky O, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371:2085–2092.
   PubMed Web of Science ®Google Scholar
• Comi G, Abramsky O, Arbizu T, et al. Oral laquinimod in patients with relapsing-remitting multiple sclersosis: 36 week double-blind extension of the multi-centre, randomized, double –blind, parallel-group placebo-controlled study. Mult Scler. 2010;16(11):1360–1366.
   PubMed Web of Science ®Google Scholar
• Comi G, Jeffery D, Kappos L, et al. Placebo controlled trial of oral laquinimod for multiple sclerosis. N Eng J Med. 2012;366:1000–1009.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Pagani E, et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg and Psych. 2013;85(8):851–859.
   PubMed Web of Science ®Google Scholar
• Vollmer TL, Sorenson PS, Selmaj K, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261:773–783.
   PubMed Web of Science ®Google Scholar
• Tumani H, Ziemssen T, Paul F, et al. Safety and tolerability of escalating doses of laquinimod, an oral immunomodulatory agent in development for treatment of relapsing-remitting multiple sclerosis. Tracking Number 14-A-514-AAN.
   Google Scholar
• clinicaltrials.gov. The efficacy and safety and tolerability of laqunimod in subjects with relapsing remitting multiple sclerosis (RRMS) (CONCERTO) [Internet]. [cited 2016 Jan 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT01707992
   Google Scholar
• clinicaltrials.gov. A phase 2 clinical study in subjects with primary progressive multiple sclerosis to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.5mg/day (experimental drug) as compared to placebo [Internet]. [cited 2016 Jan 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT02284568
   Google Scholar
• Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials. CONCERTO and ARPEGGIO trials continue study of lower-dose laquinimod [Internet]. [cited 2016 Jan 2]. Available from: http://www.tevapharm.com/news/teva_and_active_biotech_announce_discontinuation_of_higher_doses_of_laquinimod_in_two_multiple_sclerosis_trials_01_16.aspx
   Google Scholar
• Refusal of the marketing authorization for Nerventra (laquinimod). European medicines agency. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002546/WC500160120.pdf
   Google Scholar